​

Nurix Therapeutics (NRIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

NRIX Stock Forecast

Nurix Therapeutics (NRIX) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $33.50, with a high of $41.00 and a low of $26.00. This represents a 70.48% increase from the last price of $19.65.

$10 $17 $24 $31 $38 $45 High: $41 Avg: $33.5 Low: $26 Last Closed Price: $19.65

NRIX Stock Rating

Nurix Therapeutics stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (78.95%), 4 Hold (21.05%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 4 15 Strong Sell Sell Hold Buy Strong Buy

NRIX Forecast vs Benchmarks

TypeNameUpside
StockNurix Therapeutics70.48%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-114
Avg Price Target-$35.00$30.71
Last Closing Price$19.65$19.65$19.65
Upside/Downside-78.12%56.28%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25791--17
Dec, 24791--17
Nov, 24681--15
Oct, 24681--15
Sep, 24681--15
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024Etzer DaroutBMO Capital$35.00$20.0674.48%78.12%
Oct 24, 2024David DaiUBS$35.00$24.7841.24%78.12%
Oct 21, 2024Robert BurnsH.C. Wainwright$30.00$25.1919.09%52.67%
Oct 15, 2024Matthew BieglerOppenheimer$35.00$24.8740.73%78.12%
Oct 15, 2024Derek ArchilaWells Fargo$32.00$25.1627.19%62.85%
Oct 14, 2024Stephen WilleyStifel Nicolaus$34.00$24.9836.11%73.03%
Oct 11, 2024Roger SongJefferies$41.00$23.0477.95%108.65%
Sep 05, 2024Brian SkorneyRobert W. Baird$26.00$24.446.38%32.32%
Aug 14, 2024Matthew BieglerOppenheimer$27.00$21.9223.18%37.40%
Jun 27, 2024Gregory RenzaRBC Capital$26.00$20.7025.60%32.32%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 29, 2025RBC CapitalOutperformOutperformhold
Dec 05, 2024BMO CapitalOutperforminitialise
Oct 21, 2024H.C. WainwrightBuyBuyhold
Oct 15, 2024OppenheimerOutperformOutperformhold
Oct 15, 2024Wells FargoOverweightOverweighthold
Oct 14, 2024RBC CapitalOutperformOutperformhold
Oct 14, 2024Piper SandlerOverweightOverweighthold
Oct 11, 2024JefferiesBuyinitialise
Sep 04, 2024RBC CapitalBuyBuyhold
Sep 04, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 Nov 20 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 20Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$-2.76$-2.73$-3.42$-2.65$-2.88-----
Avg Forecast$-2.01$-2.54$0.59$-2.34$-2.81$-3.14$-3.37$-3.44$-2.45$-0.03
High Forecast$-2.68$-3.40$-0.38$-2.94$-3.04$-3.78$-4.53$-4.71$-4.76$-0.07
Low Forecast$-1.43$-1.81$1.55$-1.49$-2.61$-2.21$-1.82$-1.77$-1.51$-0.02
Surprise %37.31%7.48%-679.66%13.25%2.49%-----

Revenue Forecast

$0 $190M $380M $570M $760M $950M Nov 20 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 20Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$17.82M$29.75M$38.63M$76.99M$54.55M-----
Avg Forecast$14.04M$35.21M$47.31M$94.04M$54.58M$57.44M$71.12M$100.48M$245.89M$536.49M
High Forecast$10.94M$27.43M$37.85M$68.35M$41.35M$47.20M$44.47M$96.42M$172.97M$377.40M
Low Forecast$17.66M$44.28M$56.78M$140.13M$64.72M$68.99M$147.28M$104.54M$424.06M$925.25M
Surprise %26.89%-15.50%-18.36%-18.14%-0.05%-----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Nov 20 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 20Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$-43.24M$-117.19M$-166.04M$-143.95M$-193.57M-----
Avg Forecast$-109.22M$-98.03M$-226.20M$-143.95M$-193.57M$-200.83M$-291.81M$-314.78M$-164.44M$-2.30M
High Forecast$-145.82M$-117.64M$-271.43M$-172.74M$-204.03M$-253.65M$-303.86M$-316.43M$-319.36M$-4.47M
Low Forecast$-77.86M$-78.43M$-180.96M$-115.16M$-175.17M$-148.02M$-121.87M$-118.75M$-101.05M$-1.41M
Surprise %-60.41%19.55%-26.59%-------

NRIX Forecast FAQ

Is Nurix Therapeutics stock a buy?

Nurix Therapeutics stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Nurix Therapeutics is a favorable investment for most analysts.

What is Nurix Therapeutics's price target?

Nurix Therapeutics's price target, set by 19 Wall Street analysts, averages $33.5 over the next 12 months. The price target range spans from $26 at the low end to $41 at the high end, suggesting a potential 70.48% change from the previous close price of $19.65.

How does Nurix Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Nurix Therapeutics stock forecast shows a 70.48% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Nurix Therapeutics over the past three months?

  • January 2025: 41.18% Strong Buy, 52.94% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 41.18% Strong Buy, 52.94% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 40.00% Strong Buy, 53.33% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.

What is Nurix Therapeutics’s EPS forecast?

Nurix Therapeutics's average annual EPS forecast for its fiscal year ending in November is -3.14 for 2025, a 9.03% increase from the reported $-2.88 in 2024. The prediction for 2026 is $-3.37, $-3.44 for 2027, $-2.45 for 2028, and $-0.03 for 2029.

What is Nurix Therapeutics’s revenue forecast?

Nurix Therapeutics's average annual revenue forecast for its fiscal year ending in November is $57.44M for 2025, a 5.29% increase from the reported $54.55M in 2024. The forecast for 2026 is $71.12M, $100.48M for 2027, $245.89M for 2028, and $536.49M for 2029.

What is Nurix Therapeutics’s net income forecast?

For its fiscal year ending in November, Nurix Therapeutics's average annual net income forecast is $-201M for 2025, reflecting an 3.75% increase from the reported $-194M in 2024. The projection for 2026 is $-292M, $-315M for 2027, $-164M for 2028, and $-2.301M for 2029.